triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
These hormones will cause the masculinization of the phenotypically indifferent organs. When exposed to testosterone, the genital tubercle elongates to form the penis. By fusion of the urogenital folds—elongated spindle-shaped structures that contribute to the formation of the urethral groove on the belly aspect of the genital tubercle—the urogenital sinus closes completely to form the spongy urethra and the labioscrotal swellings unite to form the scrotum. The secretion of testosterone during this phase plays a decisive role in the final shaping of the penis. After birth, testosterone levels drop significantly until puberty.
Radon is an invisible, radioactive atomic gas that results from the radioactive decay of radium, which may be found in rock formations beneath buildings or in certain building materials themselves. Radon is probably the most pervasive serious hazard for indoor air in the United States and Europe. It is a major cause of lung cancer, responsible for 3–14% of cases in countries, leading to tens of thousands of deaths. Radon gas enters buildings as a soil gas. As it is a heavy gas it will tend to accumulate at the lowest level. Radon may also be introduced into a building through drinking water particularly from bathroom showers. Building materials can be a rare source of radon, but little testing is carried out for stone, rock or tile products brought into building sites; radon accumulation is greatest for well insulated homes. There are simple do-it-yourself kits for radon gas testing, but a licensed professional can also check homes. The half-life for radon is 3.8 days, indicating that once the source is removed, the hazard will be greatly reduced within a few weeks. Radon mitigation methods include sealing concrete slab floors, basement foundations, water drainage systems, or by increasing ventilation. They are usually cost effective and can greatly reduce or even eliminate the contamination and the associated health risks. Radon is measured in picocuries per liter of air (pCi/L) or becquerel per cubic meter (Bq m-3). Both are measurements of radioactivity. The World Health Organization (WHO) sets the ideal indoor radon levels at 100 Bq/m-3.
=== Olympics === There were concerns dairy products consumed during the 2008 Summer Olympics may have been contaminated. Li Changjiang, the then Director of AQSIQ reassured the international community that all the food, including dairy products, was indeed safe. "We took special quality management measures aimed at food supply for the Games."
==== Neural ==== Oxytocin secretion in response to suckling or vagino-cervical stimulation is mediated by some of these pathways; vasopressin secretion in response to cardiovascular stimuli arising from chemoreceptors in the carotid body and aortic arch, and from low-pressure atrial volume receptors, is mediated by others. In the rat, stimulation of the vagina also causes prolactin secretion, and this results in pseudo-pregnancy following an infertile mating. In the rabbit, coitus elicits reflex ovulation. In the sheep, cervical stimulation in the presence of high levels of estrogen can induce maternal behavior in a virgin ewe. These effects are all mediated by the hypothalamus, and the information is carried mainly by spinal pathways that relay in the brainstem. Stimulation of the nipples stimulates release of oxytocin and prolactin and suppresses the release of LH and FSH. Cardiovascular stimuli are carried by the vagus nerve. The vagus also conveys a variety of visceral information, including for instance signals arising from gastric distension or emptying, to suppress or promote feeding, by signalling the release of leptin or gastrin, respectively. Again, this information reaches the hypothalamus via relays in the brainstem. In addition, hypothalamic function is responsive to—and regulated by—levels of all three classical monoamine neurotransmitters, noradrenaline, dopamine, and serotonin (5-hydroxytryptamine), in those tracts from which it receives innervation.
Sources: en.wikipedia.org
1995: British geomorphologist Marjorie Sweeting published the first comprehensive Western account of China's karst, entitled Karst in China: its Geomorphology and Environment. 1995: Israeli-Canadian mathematical biologist Leah Keshet became the first female president of the international Society for Mathematical Biology. 1995: British geochemist Jane Plant became the first female deputy director of the British Geological Survey. 1995: Inspectors from the United Nations Special Commission discovered that Iraqi microbiologist Rihab Taha, nicknamed "Dr. Germ", had been overseeing a secret 10-year biological warfare development program in Iraq. 1996: American planetary scientist Margaret G. Kivelson led a team that discovered the first subsurface, saltwater ocean on an alien world, on the Jovian moon Europa. 1997: Lithuanian-Canadian primatologist Birutė Galdikas received the Tyler Prize for Environmental Achievement for her research and rehabilitation work with orangutans. Her work with orangutans, eventually spanning over 30 years, was later recognized in 2014 as one of the longest continuous scientific studies of wild animals in history. 1997: Chilean astronomer María Teresa Ruiz discovered Kelu 1, one of the first observed brown dwarfs. In recognition of her discovery, she became the first woman to receive the Chilean National Prize for Exact Sciences. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. Late 1990s: Ethiopian-American chemist Sossina M. Haile developed the first solid acid fuel cell.
== External links == International Chemical Safety Card 1104 SIDS Initial Assessment Report for 1,4-Butanediol from the Organisation for Economic Co-operation and Development (OECD) Record in the Household Products Database of NLM
Most of the finely textured beef is produced and sold by BPI, Cargill and Tyson Foods. As of March 2012 there was no labeling of the product, and only a USDA Organic label would have indicated that beef contained no "pink slime". Per BPI, the finished product is 94% to 97% lean beef (with a fat content of 3% to 6%) has a nutritional value comparable to 90% lean ground beef, is very high in protein, low in fat, and contains iron, zinc and B vitamins. Ammonia-treated LFTB typically contains 200 ppm of residual ammonia, compared to 101 ppm in conventional ground meat without LFTB. U.S. beef that contains up to 15% of the product can be labeled as "ground beef". Up to 2005, filler could make up to 25% of ground meat. In an Associated Press review, food editor and cookbook author J. M. Hirsh compared the taste of two burgers: one containing LFTB and one traditional hamburger. He described the LFTB-containing burgers as smelling the same, but being less juicy and with not as much flavor. In 2002, a United States Department of Agriculture (USDA) microbiologist argued that the product contained connective tissue and that he did not consider it to be ground beef and that it was "not nutritionally equivalent" to ground beef. BPI claims no such connective tissue is used in their product. At least since 2004, USDA regulations disallow the use of connective tissue (see § Regulation below).
Topical formulations of diphenhydramine are available, including creams, lotions, gels, sprays, and eye drops. These are used to relieve itching and have the advantage of causing fewer systemic effects (such as drowsiness) than oral forms.
=== MSG === In 1996, the FDA commissioned the Federation of American Society for Experimental Biology (FASEB) to study the effects of MSG, who concluded that MSG is safe for most people. At the time, Ajinomoto also noted the possibility that asthma patients and carriers with symptoms of Chinese restaurant syndrome symptoms may be affected, but ultimately, the safety of this group was also confirmed by subsequent test results in the United States and Australia. In 2020, Ajinomoto along with other activists launched the #RedefineCRS campaign to combat the myth that MSG is harmful to people's health, which highlights both the underlying xenophobic biases against Asian cuisine and scientific evidence that the myth is false. The FDA Food Code 2022 removed MSG from the table of common chemical hazards and associated food and control measures in retail establishments. Low-sodium salt substitutes are considered to be formulations where sodium is reduced – usually by partial or full replacement of NaCl with other chloride and non-chloride salts such as KCl, magnesium chloride, calcium chloride or potassium lactate. Monosodium glutamate (MSG) was also considered a low-sodium salt substitute.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.